Research ArticleOriginal Article
Open Access

Outcomes and characteristics of myasthenia gravis: A 10-year retrospective cross-sectional study at King Fahad Medical City

Abdulrahman Ali, Daifallah Almalki, Mamdouh A. Kotb and Reem S. Alenazi
Neurosciences Journal October 2022, 27 (4) 237-243; DOI: https://doi.org/10.17712/nsj.2022.4.20220038

References

  1. 1.↵
    1. Berrih-Aknin S.
    Myasthenia gravis, a model of organ-specific autoimmune disease. J Autoimmun 1995; 8: 139–143.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Carr AS,
    2. Cardwell CR,
    3. McCarron PO,
    4. McConville J.
    A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 2010; 10: 46.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Hemminki K,
    2. Li X,
    3. Sundquist K.
    Familial risks for diseases of myoneural junction and muscle in siblings based on hospitalizations and deaths in sweden. Twin Res Hum Genet 2006; 9: 573–579.
    OpenUrlPubMed
  4. 4.↵
    1. Algahtani H,
    2. Shirah B,
    3. Alshehri A,
    4. Al Hassani AN,
    5. Binseddeq HH,
    6. Mukhtar RM, et al.
    Clinical Presentation, Management, and Outcome in Patients With Myasthenia Gravis: A Retrospective Study From Two Tertiary Care Centers in Saudi Arabia. Cureus 2021; 13: e20765.
    OpenUrl
  5. 5.↵
    1. Gilhus NE,
    2. Verschuuren JJ.
    Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015; 14: 1023–1036.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Alanazy MH.
    Clinical features and outcomes of patients with myasthenia gravis. Neurosciences (Riyadh) 2019; 24: 176–184.
    OpenUrl
  7. 7.↵
    1. Guptill JT,
    2. Sanders DB,
    3. Evoli A.
    Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44: 36–40.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. de Meel RHP,
    2. Verschuuren JJ,
    3. Tannemaat MR.
    Distinct representation of muscle weakness in QMG and MG-ADL. Lancet Neurol 2018; 17: 204–205.
    OpenUrl
  9. 9.↵
    1. de Meel R,
    2. Raadsheer W,
    3. van Zwet E,
    4. Verschuuren J,
    5. Tannemaat M.
    Sensitivity of MG-ADL for generalized weakness in myasthenia gravis. Eur J Neurol 2019; 26: 947–950.
    OpenUrl
  10. 10.↵
    1. Meriggioli MN,
    2. Sanders DB.
    Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8: 475–490.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.
    1. Verschuuren JJ,
    2. Huijbers MG,
    3. Plomp JJ,
    4. Niks EH,
    5. Molenaar PC,
    6. Martinez-Martinez P, et al.
    Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 2013; 12: 918–923.
    OpenUrl
  12. 12.↵
    1. Binfalah MF,
    2. Alhafnawi HH,
    3. Jaradat AA,
    4. Shosha E,
    5. Alhilly AJ,
    6. Al Nidawi FK, et al.
    Clinical delineation of myasthenia gravis in the Kingdom of Bahrain. Neurosciences (Riyadh) 2022; 27: 16–23.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Barnett C,
    2. Bril V,
    3. Kapral M,
    4. Kulkarni AV,
    5. Davis AM.
    Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency. Neurology 2017; 89: 2357–2364.
    OpenUrl
  14. 14.↵
    1. Lewis RA.
    Myasthenia gravis: New therapeutic approaches based on pathophysiology. J Neurol Sci 2013; 333: 93–98.
    OpenUrl
  15. 15.↵
    1. Wolfe GI,
    2. Herbelin L,
    3. Nations S,
    4. Foster B,
    5. Bryan W,
    6. Barohn R.
    Myasthenia gravis activities of daily living profile. Neurology 1999; 52: 1487–1489.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Al-Moallem MA,
    2. Alkali NH,
    3. Hakami MA,
    4. Zaidan RM.
    Myasthenia gravis: presentation and outcome in 104 patients managed in a single institution. Ann Saudi Med. 2008; 28: 341–345.
    OpenUrlPubMed
  17. 17.↵
    1. Carr AS,
    2. Cardwell CR,
    3. McCarron PO,
    4. McConville J.
    A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC neurology 2010; 10: 1–9.
    OpenUrl
  18. 18.↵
    1. Aragonès JM,
    2. Roura-Poch P,
    3. Hernández-Ocampo EM,
    4. Alonso F,
    5. Pont-Lluelles M,
    6. Xandri I, et al.
    Myasthenia gravis: a disease of the very old. J Am Geriatr Soc 2014; 62: 196–197.
    OpenUrl
  19. 19.↵
    1. Murai H,
    2. Yamashita N,
    3. Watanabe M,
    4. Nomura Y,
    5. Motomura M,
    6. Yoshikawa H, et al.
    Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 2011; 305: 97–102.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Andersen J,
    2. Engeland A,
    3. Owe J,
    4. Gilhus N.
    Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neuro 2010; 17: 1445–1450.
    OpenUrl
  21. 21.↵
    1. Cortés-Vicente E,
    2. Álvarez-Velasco R,
    3. Segovia S,
    4. Paradas C,
    5. Casasnovas C,
    6. Guerrero-Sola A, et al.
    Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 2020; 94: e1171–e1180.
    OpenUrl
  22. 22.↵
    1. de Meel RH,
    2. Tannemaat MR,
    3. Verschuuren JJ.
    Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis. Neuromuscul Disord 2019; 29: 664–670.
    OpenUrl
  23. 23.↵
    1. Nel M,
    2. Heckmann JM
    , editors. Epidemiology and Genetics of Myasthenia Gravis. Myasthenia Gravis and Related Disorders. Springer; Cham (CH): 2018. p. 71–84.
  24. 24.↵
    1. Albuquerque EX,
    2. Pereira EF,
    3. Alkondon M,
    4. Rogers SW.
    Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009; 89: 73–120.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Anil R,
    2. Kumar A,
    3. Alaparthi S,
    4. Sharma A,
    5. Nye JL,
    6. Roy B, et al.
    Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry–The EXPLORE-MG registry. J Neurol Sci 2020; 414: 116830.
    OpenUrlPubMed
  26. 26.↵
    1. Samal P,
    2. Goyal V,
    3. Singh MB,
    4. Srivastava MP.
    MuSK (Muscle Specific Kinase) positive myasthenia: Grave prognosis or undue prejudice? Ann Indian Acad Neurol 2020; 23: 32–37.
    OpenUrl
  27. 27.↵
    1. Melzer N,
    2. Ruck T,
    3. Fuhr P,
    4. Gold R,
    5. Hohlfeld R,
    6. Marx A, et al.
    Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol 2016; 263: 1473–1494.
    OpenUrl
  28. 28.↵
    1. Mehndiratta MM,
    2. Pandey S,
    3. Kuntzer T.
    Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev. 2014; 2014: CD006986.
    OpenUrl
  29. 29.↵
    1. Skeie G,
    2. Apostolski S,
    3. Evoli A,
    4. Gilhus N,
    5. Illa I,
    6. Harms L, et al.
    Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893–902.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Evoli A,
    2. Bianchi MR,
    3. Riso R,
    4. Minicuci GM,
    5. Batocchi AP,
    6. Servidei S, et al.
    Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 2008; 1132: 76–83.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Punga AR,
    2. Flink R,
    3. Askmark H,
    4. Stålberg EV.
    Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve 2006; 34: 111–115.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Monsul NT,
    2. Patwa HS,
    3. Knorr AM,
    4. Lesser RL,
    5. Goldstein JM.
    The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 2004; 217: 131–133.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Wang L,
    2. Zhang Y,
    3. He M.
    Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol 2017; 17: 77.
    OpenUrl
  34. 34.↵
    1. Bhanushali MJ,
    2. Wuu J,
    3. Benatar M.
    Treatment of ocular symptoms in myasthenia gravis. Neurology 2008; 71: 1335–1341.
    OpenUrl
  35. 35.↵
    1. Zinman L,
    2. Ng E,
    3. Bril V.
    IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007; 68: 837–841.
    OpenUrlCrossRef
  36. 36.↵
    1. Gajdos P,
    2. Chevret S,
    3. Toyka K.
    Intravenous immunoglobulin for myasthenia gravis (Cochrane Review). Cochrane Database Syst Rev 2012; 12: CD002277.
    OpenUrlPubMed
  37. 37.↵
    1. Guptill JT,
    2. Sanders DB,
    3. Evoli A.
    Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44: 36–40.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Shibata-Hamaguchi A,
    2. Samuraki M,
    3. Furui E,
    4. Iwasa K,
    5. Yoshikawa H,
    6. Hayashi S, et al.
    Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis. Acta neurologica scandinavica. 2007; 116: 406–408.
    OpenUrlPubMed
  39. 39.↵
    1. Hatanaka Y,
    2. Hemmi S,
    3. Morgan M,
    4. Scheufele M,
    5. Claussen G,
    6. Wolfe G, et al.
    Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 2005; 65: 1508–1509.
    OpenUrl
  40. 40.↵
    1. Benatar M,
    2. Kaminski HJ.
    Evidence report: The medical treatment of ocular myasthenia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007; 68: 2144–2149.
    OpenUrl
  41. 41.↵
    1. Evoli A,
    2. Tonali PA,
    3. Padua L,
    4. Monaco ML,
    5. Scuderi F,
    6. Batocchi AP, et al.
    Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126: 2304–2311.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Lavrnic D,
    2. Losen M,
    3. Vujic A,
    4. De Baets M,
    5. Hajdukovic L,
    6. Stojanovic V, et al.
    The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005; 76: 1099–1102.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Hart IK,
    2. Sathasivam S,
    3. Sharshar T.
    Immunosuppressive agents for myasthenia gravis. Cochrane database of systematic reviews 2007; 4: CD005224.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section